Sonitor Introduces SonitorBLU™ and SonitorMOBILE™
17.4.2023 19:35:00 EEST | Business Wire | Press release
Sonitor® Technologies today announced expansion of its market leading Sense™ platform with SonitorBLU, a proprietary Bluetooth Low Energy (BLE) solution for use cases when zonal accuracy is required, and SonitorMOBILE, a location visibility platform for positioning smart devices, combining Sonitor’s ultrasound technology with BLE to provide best-in-class accuracy, effectively turning a smart phone into an RTLS tag. The company made the announcement at the HIMSS Global Health Conference where it is exhibiting from April 18-20.
Sonitor’s new portfolio offers a tiered approach to the challenges faced by healthcare providers. These range from simple asset tracking to more demanding applications that require speed and accuracy such as patient flow and clinical workflow, as well as the critical need to ensure staff safety. As with Sense, these new products offer advanced analytics for workflow insights, and appropriate staffing assignments that help increase hospital capacity and improve patient and staff satisfaction.
“Sonitor is excited to invite healthcare providers, technology partners and all HIMSS attendees to our booth where we will be showcasing the SonitorBLU, Sonitor Sense and SonitorMOBILE suite of products,” said Matt Crane, Chief Commercial Officer, North America/CEO, Sonitor Inc. “In addition, we have recently expanded our team of clinical and technology experts to customize Sonitor’s solutions to meet customers’ strategic objectives and budgets.”
With SonitorBLU, hospitals have an easy-to-install platform to address use cases such as asset tracking when near real-time data flow is sufficient. With no cabling, installation is simple and fast, and the system can be up and reporting locations in less than a day. SonitorMOBILE, combines Sonitor’s patented ultrasound technology, SonitorULE™, and BLE to provide centimeter level accuracy with refresh rates of 1-2 seconds, to “move at the speed of a nurse™,” for highly demanding use cases.
About Sonitor
Sonitor Technologies AS is the leading provider of accurate, affordable, and easy to use Real Time Locating Systems (RTLS) with wearables for staff safety and workforce enablement. The first and only company to commercialize low energy ultrasound as the primary locating technology with proven 99.9% location accuracy, SonitorULE™, is more affordable than traditional RTLS platforms using radio (RF or RFID) or infrared (IR) technologies. Based on its proven record for uptime performance in clinical settings, Sonitor is the only RTLS company to offer a 5-year warranty as standard on its infrastructure technology. The company received a high ranking in the 2023 Best in KLAS RTLS report, second only to the winner, Sonitor partner Securitas Healthcare. Sonitor also earned certification as a “Great Place to Work®” in 2022 and was recognized as among the top companies poised for growth based on innovation and customer alignment in Frost & Sullivan’s Radar™ Industry Report for Indoor Positioning Systems (IPS). To learn more visit www.sonitor.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005644/en/
Contact information
Dan Conley
Beacon Communications dconley@beaconpr.com
+1-312-593-8461
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i
Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release
Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom